Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc (NQ: CNTX )

0.8800 +0.0400 (+4.76%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 342,023
Open 0.9400
Bid (Size) 0.8002 (13)
Ask (Size) 0.8900 (13)
Prev. Close 0.8400
Today's Range 0.8210 - 0.9400
52wk Range 0.4700 - 2.520
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference
Via ACCESSWIRE

Performance

YTD
+30.54%
+30.54%
1 Month
+51.70%
+51.70%
3 Month
+13.10%
+13.10%
6 Month
-37.14%
-37.14%
1 Year
-57.07%
-57.07%

More News

Read More
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference
Via Benzinga
Context Therapeutics to Participate in Two April 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Context Therapeutics Inc.
Via GlobeNewswire
$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Insiders Buying AmeriServ Financial And 2 Other Penny Stocks
Via Benzinga
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
Via Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies
Via Benzinga
Dow Turns Higher; Nasdaq Jumps 100 Points
Via Benzinga
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
Via Benzinga
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.